ALBUQUERQUE, N.M., Oct. 26 /PRNewswire/ -- Exagen Diagnostics, Inc., which
develops and commercializes genomic marker-based in vitro diagnostic (IVD)
kits for disease prognosis and prediction of treatment response, today
announced that James McClintic has joined the company as president and CEO.
McClintic succeeds Exagen founding CEO Waneta Tuttle, who will turn her
attention to Southwest Medical Ventures, the venture development company she
owns. Tuttle will continue as a member of the Exagen board of directors.
"Exagen has reached an important milestone and is now poised to begin
commercializing its diagnostic tests on a global scale," said Tuttle. "With
his depth of knowledge in the clinical laboratory arena and a proven track
record of growing start-up companies, Jim McClintic is the ideal person to
lead Exagen through its next phase of development."
Before joining Exagen, McClintic served as president and CEO of Esoterix,
Inc., which performs laboratory services involving diagnosis and monitoring of
serious diseases and conditions including asthma, bleeding disorders, cancer,
diabetes and infectious diseases. During his six-year tenure there, McClintic
grew annual revenues from $50 million to $120 million and orchestrated the
sale of Esoterix to LabCorp, Inc. for $150 million. Previously, McClintic was
regional president of eastern operations for Corning Clinical Labs, now Quest.
He also held positions as president of SciCor, Inc., vice president of sales
for the eastern zone of Bristol-Myers Squibb, and various sales and marketing
management positions with E.R. Squibb & Sons, Inc.
"Exagen's approach to genomic diagnostic tests is truly state of the art
and represents an exciting opportunity to put high science in the hands of
physicians who will use it to give patients a significantly better quality of
life," said McClintic. "I welcome the opportunity to devise the company's
strategic direction for the next phase of growth and ultimately, to elevate
Exagen's place in the market."
Exagen's products address the rapidly growing molecular diagnostics
segment of the $22 billion in vitro diagnostics market. Next year, the company
will launch its Key2(TM) Breast Cancer Prognostic Tests, the first and only
reagents to detect changes in DNA copy number in both hormonepositive and
hormone-negative patients using an improved FISH assay. In June, Exagen closed
a Series B round of financing with investors Tullis- Dickerson & Co., vSpring
Capital and Wasatch Venture Fund.
"This transition reflects the success of Exagen to date," said Thomas
Dickerson, chairman of Tullis-Dickerson & Co. and chairman of the Exagen board
of directors. "Dr. Tuttle's extraordinary vision and determination have
enabled the company to assemble its technology platform and to bring its
initial products into clinical trials that enable FDA clearance. Jim
McClintic's proven successes in growing diagnostic franchises and in
commercializing products will ensure the company's future."
About Exagen Diagnostics, Inc.
As an emerging leader in the development of prognostic and predictive in
vitro diagnostic (IVD) kits, Exagen Diagnostics is uniquely able to discover,
validate and productize small sets of genomic markers for use in oncology,
infectious disease and other indications. Exagen aims to commercialize IVD
kits that can be performed by existing diagnostic laboratories and to develop
tests that accompany the launch of new therapeutics and/or support
pharmaceutical R&D/Phase IV. For more information, visit
SOURCE Exagen Diagnostics, Inc.